Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AKRO Stock Forecast 2025-2026
$41.00
Current Price
$3.26B
Market Cap
Buy 12
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to AKRO Price Targets
+165.9%
To High Target of $109.00
+82.9%
To Median Target of $75.00
+46.3%
To Low Target of $60.00
AKRO Price Momentum
+8.8%
1 Week Change
-4.0%
1 Month Change
+107.7%
1 Year Change
+47.4%
Year-to-Date Change
-29.8%
From 52W High of $58.40
+129.6%
From 52W Low of $17.86
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Akero (AKRO) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on AKRO and similar high-potential opportunities.
Latest AKRO Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, AKRO has a bullish consensus with a median price target of $75.00 (ranging from $60.00 to $109.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $41.00, the median forecast implies a 82.9% upside. This outlook is supported by 12 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Eliana Merle at UBS, projecting a 165.9% upside. Conversely, the most conservative target is provided by Liisa Bayko at Evercore ISI Group, suggesting a 46.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AKRO Analyst Ratings
12
Buy
0
Hold
0
Sell
AKRO Price Target Range
Low
$60.00
Average
$75.00
High
$109.00
Current: $41.00
Latest AKRO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AKRO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 3, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $75.00 |
| Jan 31, 2025 | UBS | Eliana Merle | Buy | Maintains | $109.00 |
| Jan 30, 2025 | B of A Securities | Alexandria Hammond | Buy | Upgrade | $63.00 |
| Jan 28, 2025 | Morgan Stanley | Michael Ulz | Overweight | Maintains | $96.00 |
| Jan 28, 2025 | Citigroup | Jonathan Woo | Buy | Maintains | $80.00 |
| Jan 28, 2025 | Canaccord Genuity | Edward Nash | Buy | Maintains | $73.00 |
| Jan 27, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $72.00 |
| Jan 16, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $50.00 |
| Nov 18, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $50.00 |
| Nov 18, 2024 | Citigroup | Jonathan Woo | Buy | Initiates | $65.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $50.00 |
| Sep 17, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $50.00 |
| Aug 12, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $50.00 |
| Jun 20, 2024 | Cantor Fitzgerald | Prakhar Agrawal | Overweight | Reiterates | $0.00 |
| Jun 12, 2024 | Cantor Fitzgerald | Prakhar Agrawal | Overweight | Reiterates | $0.00 |
| Jun 11, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $50.00 |
| Jun 11, 2024 | Wolfe Research | Andy Chen | Outperform | Initiates | $0.00 |
| May 15, 2024 | Evercore ISI Group | Liisa Bayko | Outperform | Maintains | $38.00 |
| May 13, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $50.00 |
| May 13, 2024 | Canaccord Genuity | Edward Nash | Buy | Maintains | $56.00 |
Akero Therapeutics Inc. (AKRO) Competitors
The following stocks are similar to Akero based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Akero Therapeutics Inc. (AKRO) Financial Data
Akero Therapeutics Inc. has a market capitalization of $3.26B with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -39.2%.
Valuation Metrics
Market Cap
$3.26B
Enterprise Value
$2.56B
P/E Ratio
0.0x
PEG Ratio
-9.6x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+22.8%
Current Ratio
19.4x
Debt/Equity
4.8x
ROE
-39.2%
ROA
-25.4%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Akero Therapeutics Inc. (AKRO) Business Model
About Akero Therapeutics Inc.
What They Do
Develops treatments for serious metabolic diseases.
Business Model
Akero Therapeutics focuses on developing and commercializing innovative therapeutics for serious metabolic diseases, particularly non-alcoholic steatohepatitis (NASH). The company generates revenue through the research and development of its drug candidates, aiming to address significant unmet medical needs in the healthcare sector.
Additional Information
With a strong emphasis on understanding liver pathophysiology and medicinal chemistry, Akero Therapeutics is well-positioned to capitalize on the growing demand for effective treatments for metabolic disorders. Their investigational drugs target key metabolic and immune pathways, potentially improving liver health amid the rising global incidence of these diseases.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
63
CEO
Dr. Andrew Cheng M.D., Ph.D.
Country
United States
IPO Year
2019
Website
akerotx.comAkero Therapeutics Inc. (AKRO) Latest News & Analysis
Latest News
Quick Summary
Moore Law, PLLC is investigating potential claims against certain companies, indicating possible shareholder litigation. Investors should monitor developments for implications on affected firms.
Why It Matters
The investigation by Moore Law could signal potential legal issues for companies involved, affecting their stock prices and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of Akero Therapeutics (NASDAQ:AKRO) who purchased securities before September 13, 2022.
Why It Matters
The investigation into Akero Therapeutics could indicate potential legal issues or financial misconduct, impacting stock performance and investor sentiment regarding the company.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of Akero Therapeutics (NASDAQ:AKRO) who purchased shares before September 13, 2022.
Why It Matters
Investigation into Akero Therapeutics may indicate potential legal issues or financial irregularities, impacting stock performance and investor sentiment.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating claims for investors who bought Akero Therapeutics (NASDAQ:AKRO) securities before September 13, 2022. Further details are available on their website.
Why It Matters
Ongoing investigations into Akero Therapeutics may signal potential legal or financial issues, impacting stock performance and investor confidence in the company.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Akero Therapeutics (NASDAQ:AKRO) investors who bought shares before September 13, 2022. More info available at bgandg.com/AKRO.
Why It Matters
The investigation into Akero Therapeutics may indicate potential legal issues or financial irregularities, which could impact stock performance and investor confidence.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors in Akero Therapeutics (NASDAQ:AKRO) who bought shares before September 13, 2022.
Why It Matters
The investigation into Akero Therapeutics may indicate potential legal issues or financial risks, impacting stock performance and investor sentiment.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About AKRO Stock
What is Akero Therapeutics Inc.'s (AKRO) stock forecast for 2025?
Based on our analysis of 13 Wall Street analysts, Akero Therapeutics Inc. (AKRO) has a median price target of $75.00. The highest price target is $109.00 and the lowest is $60.00.
Is AKRO stock a good investment in 2025?
According to current analyst ratings, AKRO has 12 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $41.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AKRO stock?
Wall Street analysts predict AKRO stock could reach $75.00 in the next 12 months. This represents a 82.9% increase from the current price of $41.00. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Akero Therapeutics Inc.'s business model?
Akero Therapeutics focuses on developing and commercializing innovative therapeutics for serious metabolic diseases, particularly non-alcoholic steatohepatitis (NASH). The company generates revenue through the research and development of its drug candidates, aiming to address significant unmet medical needs in the healthcare sector.
What is the highest forecasted price for AKRO Akero Therapeutics Inc.?
The highest price target for AKRO is $109.00 from Eliana Merle at UBS, which represents a 165.9% increase from the current price of $41.00.
What is the lowest forecasted price for AKRO Akero Therapeutics Inc.?
The lowest price target for AKRO is $60.00 from Liisa Bayko at Evercore ISI Group, which represents a 46.3% increase from the current price of $41.00.
What is the overall AKRO consensus from analysts for Akero Therapeutics Inc.?
The overall analyst consensus for AKRO is bullish. Out of 13 Wall Street analysts, 12 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $75.00.
How accurate are AKRO stock price projections?
Stock price projections, including those for Akero Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 9:40 AM UTC